Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
Net product revenue of DEXTENZA for the quarter was $12.1 million, a 9% increase over the second quarter of 2021.
- Net product revenue of DEXTENZA for the quarter was $12.1 million, a 9% increase over the second quarter of 2021.
- Net product revenue of DEXTENZA in the second quarter of 2022 was $12.1 million versus $11.1 million in the comparable quarter of 2021, reflecting a 9% increase.
- Non-cash charges for stock-based compensation and depreciation and amortization were $4.8 million in the second quarter of 2022 versus $4.9 million for the comparable quarter of 2021.
- Members of the Ocular Therapeutix management team will host a live conference call and webcast today at 4:30 pm Eastern Time to review the Company's financial results and provide a general business update.